Profile data is unavailable for this security.
About the company
HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED is a China-based investment holding company principally involved in the the research and development, production and sale of pharmaceutical products. The Company’s main products include Oulanning, Ameining, Pulaile, Zefei, Xinwei, Xinmei, Zetan, Mailingda, Hengjie, Hengsen, Fulaidi and Ruibote, among others. The Company’s products are mainly used for central nervous system disease, oncology, anti-infection, diabetes, digestive tract and cardiovascular treatment. The Company distributes its products in domestic market.
- Revenue in HKD (TTM)10.93bn
- Net income in HKD3.54bn
- Incorporated2015
- Employees9.12k
- LocationHansoh Pharmaceutical Group Company Ltd287 Xiangke Road, Pudong New DistrictSHANGHAI 201210ChinaCHN
- Websitehttp://www.hspharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sino Biopharmaceutical Ltd | 28.33bn | 2.00bn | 52.08bn | 25.81k | 23.11 | 1.58 | 8.57 | 1.84 | 0.1198 | 0.148 | 1.53 | 1.75 | 0.4104 | 2.31 | 5.73 | 1,097,763.00 | 7.23 | 13.29 | 13.37 | 22.05 | 80.95 | 79.78 | 17.61 | 27.26 | 0.9649 | 7.33 | 0.2479 | 24.88 | -8.97 | 4.63 | -27.38 | -27.22 | -- | 1.15 |
WuXi Biologics (Cayman) Inc | 18.42bn | 3.68bn | 57.42bn | 12.74k | 16.14 | 1.32 | 10.71 | 3.12 | 0.8354 | 0.8354 | 4.24 | 10.24 | 0.321 | 5.04 | 2.85 | 1,445,744.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | -- | 11.56 | 46.38 | -23.09 | 40.07 | -- | -- |
Innovent Biologics Inc | 6.71bn | -1.11bn | 63.53bn | 4.87k | -- | 4.69 | 1,212.02 | 9.47 | -0.7047 | -0.7047 | 4.30 | 8.35 | 0.3248 | 0.9481 | 7.85 | 1,377,359.00 | -5.38 | -13.06 | -6.80 | -15.85 | 81.69 | 84.51 | -16.56 | -43.44 | 2.78 | -- | 0.2242 | -- | 36.21 | 265.79 | 52.83 | -- | -- | -- |
CSPC Pharmaceutical Group Ltd | 34.01bn | 6.35bn | 78.69bn | 23.50k | 12.34 | 2.19 | 10.13 | 2.31 | 0.5348 | 0.5348 | 2.86 | 3.02 | 0.7144 | 3.26 | 6.21 | 1,447,078.00 | 13.79 | 16.08 | 18.50 | 21.57 | 70.51 | 72.95 | 19.31 | 19.63 | 2.32 | -- | 0.0198 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
Hansoh Pharmaceutical Group Company Ltd | 10.93bn | 3.54bn | 102.21bn | 9.12k | 29.32 | 3.66 | 25.94 | 9.36 | 0.5872 | 0.5872 | 1.81 | 4.70 | 0.3206 | 2.01 | 2.99 | 1,197,526.00 | 10.40 | 11.58 | 12.24 | 13.98 | 89.84 | 90.78 | 32.44 | 29.28 | 4.12 | -- | 0.143 | -- | 7.69 | 5.52 | 26.85 | 11.49 | -- | -- |
Beigene Ltd | 19.25bn | -6.90bn | 130.59bn | 10.60k | -- | 4.51 | -- | 6.79 | -5.12 | -5.12 | 14.11 | 20.37 | 0.4036 | 1.87 | 9.26 | -- | -14.47 | -26.72 | -19.80 | -33.85 | 73.40 | 83.19 | -35.86 | -120.76 | 2.09 | -- | 0.2003 | -- | 73.65 | 65.47 | 56.00 | -- | 33.46 | -- |
Data as of Apr 26 2024. Currency figures normalised to Hansoh Pharmaceutical Group Company Ltd's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 29 Feb 2024 | 69.42m | 1.17% |
FIL Investment Management (Hong Kong) Ltd.as of 29 Feb 2024 | 38.65m | 0.65% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 38.02m | 0.64% |
UBS Asset Management (Hong Kong) Ltd.as of 29 Feb 2024 | 27.29m | 0.46% |
Fidelity Management & Research (Hong Kong) Ltd.as of 31 Jan 2024 | 26.67m | 0.45% |
BlackRock Fund Advisorsas of 04 Apr 2024 | 22.25m | 0.38% |
Strategic Advisers LLCas of 29 Feb 2024 | 17.13m | 0.29% |
Hermes Investment Management Ltd.as of 29 Feb 2024 | 16.61m | 0.28% |
BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 15.42m | 0.26% |
Hang Seng Investment Management Ltd.as of 03 Apr 2024 | 14.05m | 0.24% |
More ▼
Data from 31 Dec 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.